For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a ...

Executives from Celldex Therapeutics (NASDAQ:CLDX) outlined a busy year of clinical and development milestones at the TD ...

Xeris Biopharma benefits from the FDA's CRL to Corcept's relacorilant, removing a major competitive threat to Recorlev sales ...

CEO Christopher Viehbacher told investors at TD Cowen’s 46th Annual Healthcare Conference that the company is focused on ...

FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression‑free survival and overall survival versus standard ...

FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens ...

Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare Conference. For next session or first session of the day, actually, very ...

Avonex is a prescription drug that treats relapsing forms of multiple sclerosis (MS) in adults, such as relapsing-remitting MS, active secondary progressive MS, and clinically isolated syndrome.